387 related articles for article (PubMed ID: 9865916)
1. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients.
Lai CL; Tsai CM; Tsai TT; Kuo BI; Chang KT; Fu HT; Perng RP; Chen JY
Clin Cancer Res; 1998 Dec; 4(12):3025-30. PubMed ID: 9865916
[TBL] [Abstract][Full Text] [Related]
2. The detection of quantitative serum p53 protein in lung cancer.
Sen E; Gönüllü U; Akar N
Tuberk Toraks; 2005; 53(3):231-7. PubMed ID: 16258881
[TBL] [Abstract][Full Text] [Related]
3. The role of circulating anti-p53 antibodies in patients with advanced non-small cell lung cancer and their correlation to clinical parameters and survival.
Bergqvist M; Brattström D; Larsson A; Hesselius P; Brodin O; Wagenius G
BMC Cancer; 2004 Sep; 4():66. PubMed ID: 15367333
[TBL] [Abstract][Full Text] [Related]
4. Serum p53 antibodies: predictors of survival in small-cell lung cancer?
Murray PV; Soussi T; O'Brien ME; Smith IE; Brossault S; Norton A; Ashley S; Tavassoli M
Br J Cancer; 2000 Dec; 83(11):1418-24. PubMed ID: 11076647
[TBL] [Abstract][Full Text] [Related]
5. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation.
Winter SF; Minna JD; Johnson BE; Takahashi T; Gazdar AF; Carbone DP
Cancer Res; 1992 Aug; 52(15):4168-74. PubMed ID: 1322237
[TBL] [Abstract][Full Text] [Related]
6. p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer.
Schneider J; Presek P; Braun A; Bauer P; Konietzko N; Wiesner B; Woitowitz HJ
Br J Cancer; 1999 Aug; 80(12):1987-94. PubMed ID: 10471051
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of p53 autoantibodies in lung cancer during therapy: relationship to response to treatment.
Zalcman G; Schlichtholz B; Trédaniel J; Urban T; Lubin R; Dubois I; Milleron B; Hirsch A; Soussi T
Clin Cancer Res; 1998 Jun; 4(6):1359-66. PubMed ID: 9626451
[TBL] [Abstract][Full Text] [Related]
8. Serum anti-p53 autoantibodies in pleural malignant mesothelioma, lung cancer and non-neoplastic lung diseases.
Neri M; Betta P; Marroni P; Filiberti R; Cafferata M; Mereu C; Ivaldi G; Montanaro F; Puntoni R; Paganuzzi M
Lung Cancer; 2003 Feb; 39(2):165-72. PubMed ID: 12581569
[TBL] [Abstract][Full Text] [Related]
9. Serum anti-p53 antibody detection in carcinomas and the predictive values of serum p53 antibodies, carcino-embryonic antigen and carbohydrate antigen 12-5 in the neoadjuvant chemotherapy treatment for III stage non-small cell lung cancer patients.
Yu DH; Li JH; Wang YC; Xu JG; Pan PT; Wang L
Clin Chim Acta; 2011 May; 412(11-12):930-5. PubMed ID: 21277290
[TBL] [Abstract][Full Text] [Related]
10. Prognostic implications of circulating anti-p53 antibodies in lung cancer--a review.
Kumar S; Mohan A; Guleria R
Eur J Cancer Care (Engl); 2009 May; 18(3):248-54. PubMed ID: 19432918
[TBL] [Abstract][Full Text] [Related]
11. Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer.
Trivers GE; De Benedetti VM; Cawley HL; Caron G; Harrington AM; Bennett WP; Jett JR; Colby TV; Tazelaar H; Pairolero P; Miller RD; Harris CC
Clin Cancer Res; 1996 Oct; 2(10):1767-75. PubMed ID: 9816128
[TBL] [Abstract][Full Text] [Related]
12. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma.
Shimada H; Takeda A; Arima M; Okazumi S; Matsubara H; Nabeya Y; Funami Y; Hayashi H; Gunji Y; Suzuki T; Kobayashi S; Ochiai T
Cancer; 2000 Oct; 89(8):1677-83. PubMed ID: 11042560
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of serum p53 antibodies in squamous cell carcinoma of the lung.
Komiya T; Hirashima T; Takada M; Masuda N; Yasumitsu T; Nakagawa K; Hosono Y; Kikui M; Tsuji S; Fukuoka M; Kawase I
Anticancer Res; 1997; 17(5B):3721-4. PubMed ID: 9427768
[TBL] [Abstract][Full Text] [Related]
14. The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters.
Gao RJ; Bao HZ; Yang Q; Cong Q; Song JN; Wang L
Breast Cancer Res Treat; 2005 Sep; 93(2):111-5. PubMed ID: 16187230
[TBL] [Abstract][Full Text] [Related]
15. Autoantibodies against tumour suppressor protein p53 in pleural effusions of patients with tuberculosis pleurisy.
Wang L; Chang YH; Lee YL; Shih CM; Hsu YT; Shen GH; Haung ML; Shiau MY
Ann Clin Biochem; 2007 Jan; 44(Pt 1):57-62. PubMed ID: 17270093
[TBL] [Abstract][Full Text] [Related]
16. Autoantibodies against P53 protein in patients with transitional cell carcinoma of the bladder.
Sanchez-Carbayo M; Chulia MT; Niveiro M; Aranda I; Mira A; Soria F
Anticancer Res; 1999; 19(4C):3531-7. PubMed ID: 10629648
[TBL] [Abstract][Full Text] [Related]
17. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
[TBL] [Abstract][Full Text] [Related]
18. [Serum anti-P53 antibodies (AB-anti-P53) in patients with advanced non-small cell lung cancer (NSCLC)].
Skrzypski M; Szymanowska A; Janowicz A; Dziadziuszko R; Ramlau R; Kozielski J; Pilarska-Machowicz A; Dobrzańska Z; Bigda J; Krzakowski M; Jassem E; Jassem J
Pneumonol Alergol Pol; 2002; 70(7-8):353-8. PubMed ID: 12708076
[TBL] [Abstract][Full Text] [Related]
19. The serum ferritin concentration is a significant prognostic indicator of survival in primary lung cancer.
Milman N; Pedersen LM
Oncol Rep; 2002; 9(1):193-8. PubMed ID: 11748482
[TBL] [Abstract][Full Text] [Related]
20. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer.
Kawasaki M; Nakanishi Y; Kuwano K; Yatsunami J; Takayama K; Hara N
Clin Cancer Res; 1997 Jul; 3(7):1195-200. PubMed ID: 9815799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]